Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lee M Kaplan

Showing results (51-60 of 91) with videos related to

Pageof 10
Sort By:
International Journal of Obesity (2005)|March 3, 2026
Weight-related changes in MRI-derived measures of body composition and liver steatosis: a large-scale analysis for obesity trial designMagdalena Nowak, Luis Núñez, Tim Pagliaro, et al.
Obesity (Silver Spring, Md.)|October 21, 2022
Obstacles and opportunities in managing coexisting obesity and CKD: Report of a scientific workshop cosponsored by the National Kidney Foundation and The Obesity SocietyAllon N Friedman, Philip R Schauer, Srinivasan Beddhu, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|October 24, 2022
Obstacles and Opportunities in Managing Coexisting Obesity and CKD: Report of a Scientific Workshop Cosponsored by the National Kidney Foundation and The Obesity SocietyAllon N Friedman, Philip R Schauer, Srinivasan Beddhu, et al.
Diabetes Care|August 14, 2016
Endoscopic Duodenal Mucosal Resurfacing for the Treatment of Type 2 Diabetes: 6-Month Interim Analysis From the First-in-Human Proof-of-Concept StudyHarith Rajagopalan, Alan D Cherrington, Christopher C Thompson, et al.
Population Health Management|April 2, 2025
Perspectives on Obesity Management and the Use of Anti-Obesity Medicine from US Employees and Employers: Results from the OBSERVE StudyJamy Ard, Lee M Kaplan, Scott Kahan, et al.
Nature Medicine|June 10, 2024
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trialArun J Sanyal, Lee M Kaplan, Juan P Frias, et al.
Obesity (Silver Spring, Md.)|November 4, 2024
Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™-1 and -2)Sean Wharton, Carel W le Roux, Mikhail N Kosiborod, et al.
Obesity (Silver Spring, Md.)|April 25, 2025
Perceptions of anti-obesity medications among people with obesity and healthcare providers in the US: Findings from the OBSERVE StudyLee M Kaplan, Kimberly Gudzune, Jamy Ard, et al.
Obesity (Silver Spring, Md.)|November 1, 2017
Perceptions of Barriers to Effective Obesity Care: Results from the National ACTION StudyLee M Kaplan, Angela Golden, Kimberly Jinnett, et al.
The Journal of Clinical Endocrinology and Metabolism|April 12, 2012
Melanocortin-4 receptor signaling is required for weight loss after gastric bypass surgeryIda J Hatoum, Nicholas Stylopoulos, Amanda M Vanhoose, et al.
Pageof 10

Showing results (51-60 of 91) with videos related to

Sort By:
Pageof 10
International Journal of Obesity (2005)|March 3, 2026
Weight-related changes in MRI-derived measures of body composition and liver steatosis: a large-scale analysis for obesity trial designMagdalena Nowak, Luis Núñez, Tim Pagliaro, et al.
Obesity (Silver Spring, Md.)|October 21, 2022
Obstacles and opportunities in managing coexisting obesity and CKD: Report of a scientific workshop cosponsored by the National Kidney Foundation and The Obesity SocietyAllon N Friedman, Philip R Schauer, Srinivasan Beddhu, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|October 24, 2022
Obstacles and Opportunities in Managing Coexisting Obesity and CKD: Report of a Scientific Workshop Cosponsored by the National Kidney Foundation and The Obesity SocietyAllon N Friedman, Philip R Schauer, Srinivasan Beddhu, et al.
Diabetes Care|August 14, 2016
Endoscopic Duodenal Mucosal Resurfacing for the Treatment of Type 2 Diabetes: 6-Month Interim Analysis From the First-in-Human Proof-of-Concept StudyHarith Rajagopalan, Alan D Cherrington, Christopher C Thompson, et al.
Population Health Management|April 2, 2025
Perspectives on Obesity Management and the Use of Anti-Obesity Medicine from US Employees and Employers: Results from the OBSERVE StudyJamy Ard, Lee M Kaplan, Scott Kahan, et al.
Nature Medicine|June 10, 2024
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trialArun J Sanyal, Lee M Kaplan, Juan P Frias, et al.
Obesity (Silver Spring, Md.)|November 4, 2024
Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™-1 and -2)Sean Wharton, Carel W le Roux, Mikhail N Kosiborod, et al.
Obesity (Silver Spring, Md.)|April 25, 2025
Perceptions of anti-obesity medications among people with obesity and healthcare providers in the US: Findings from the OBSERVE StudyLee M Kaplan, Kimberly Gudzune, Jamy Ard, et al.
Obesity (Silver Spring, Md.)|November 1, 2017
Perceptions of Barriers to Effective Obesity Care: Results from the National ACTION StudyLee M Kaplan, Angela Golden, Kimberly Jinnett, et al.
The Journal of Clinical Endocrinology and Metabolism|April 12, 2012
Melanocortin-4 receptor signaling is required for weight loss after gastric bypass surgeryIda J Hatoum, Nicholas Stylopoulos, Amanda M Vanhoose, et al.
Pageof 10